Mersana Therapeutics, Inc. Stock News

Concerns related to safety risks around ILD/pneumonitis are overblown in a disease of high unmet needs. I believe clinical benefits outweigh potential safety overhang, and key studies have put in the

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod

CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Jason Fredette - SVP, IR and Corporate Communications Anna Protopapas - Pre

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d

CAMBRIDGE, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d

First Immunosynthen ADC product candidate enters the clinic First Immunosynthen ADC product candidate enters the clinic

Mersana has excellent ADC science. A number of big pharma have bought into the science.

Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.  The analyst says the topline registrational data (expected in mid-2023) from the U

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth

CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-